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The p38 mitogen-activated protein kinase (MAPK) signaling pathway, acting through the downstream kinase
MK2, regulates the stability of many proinflammatory mRNAs that contain adenosine/uridine-rich elements
(AREs). It is thought to do this by modulating the expression or activity of ARE-binding proteins that regulate
mRNA turnover. MK2 phosphorylates the ARE-binding and mRNA-destabilizing protein tristetraprolin (TTP) at
serines 52 and 178. Here we show that the p38 MAPK pathway regulates the subcellular localization and stability
of TTP protein. A p38 MAPK inhibitor causes rapid dephosphorylation of TTP, relocalization from the cytoplasm
to the nucleus, and degradation by the 20S/26S proteasome. Hence, continuous activity of the p38 MAPK pathway
is required to maintain the phosphorylation status, cytoplasmic localization, and stability of TTP protein. The
regulation of both subcellular localization and protein stability is dependent onMK2 and on the integrity of serines
52 and 178. Furthermore, the extracellular signal-regulated kinase (ERK) pathway synergizes with the p38 MAPK
pathway to regulate both stability and localization of TTP. This effect is independent of kinases that are known to
be synergistically activated by ERK and p38 MAPK. We present a model for the actions of TTP and the p38 MAPK
pathway during distinct phases of the inflammatory response.
The tandem zinc finger protein tristetraprolin (TTP; also
known as Nup475, Tis11, or Zfp36) (23, 26, 40, 46, 62) is
expressed in activated monocytic cells (13, 47) and T lympho-
cytes (49, 51). It functions to regulate the expression of tumor
necrosis factor  (TNF-) by binding to a conserved adeno-
sine/uridine-rich element (ARE) within the 3-untranslated re-
gion of TNF- mRNA (13, 31, 32, 36, 47). TTP promotes both
mRNA deadenylation and 3 to 5 degradation of the mRNA
body (35, 37–39), consistent with its ability to recruit several
factors involved in these processes (14, 25, 39, 45). The pivotal
role of TTP in the regulation of TNF- is illustrated by the
proinflammatory phenotype of a TTP/ mouse strain, in
which chronic overexpression of TNF- by macrophages re-
sults in severe polyarthritis and cachexia (11, 13, 57). TTP has
also been implicated in the posttranscriptional regulation of
granulocyte-macrophage colony-stimulating factor (12), inter-
leukin-2 (51), cyclooxygenase 2 (COX-2) (50), and inducible
nitric oxide synthase (24). It may also regulate its own expres-
sion by binding to an ARE in the 3 untranslated region of TTP
mRNA (60). The minimum binding site of TTP is the
nonameric sequence UUAUUUAUU (2, 3, 38, 65), and it is
likely that additional posttranscriptional targets of TTP con-
taining this sequence remain to be identified.
The p38 mitogen-activated protein kinase (MAPK) and its
downstream kinase MK2 play a central role in the posttran-
scriptional regulation of inflammatory gene expression in my-
eloid and other cells (5, 16, 20–22, 33, 34, 54). We and others
have therefore investigated interactions of the p38 MAPK
pathway with TTP. In a mouse macrophage-like cell line,
RAW 264.7, the expression of TTP was dependent on p38
MAPK, at least in part due to p38 MAPK-dependent stabili-
zation of TTP mRNA (47, 60). TTP can be phosphorylated in
vitro by p38 MAPK itself (8, 10) or by MK2 (47). Two major
sites of MK2-mediated phosphorylation of mouse TTP in vitro
and in vivo were identified as serines 52 and 178 (15; T. San-
talucia, M. Brook, E. Hitti, G. Sully, R. Wait, C. R. Tchen,
C. J. A. Asensio, M. Gaestel, J. Saklavala, and A. R. Clark,
unpublished data). These phosphorylations were shown to re-
sult in the recruitment of 14-3-3 proteins, functional adaptors
that specifically interact with certain serine- or threonine-phos-
phorylated proteins (4, 15). The recruitment of 14-3-3 proteins
led to exclusion of TTP from stress granules (56), cytoplasmic
structures at which translationally stalled transcripts accumu-
late under conditions of environmental stress (29). The phos-
phorylation of TTP and its exclusion from stress granules were
associated with stabilization of an ARE-containing reporter
mRNA (56). However, a more recent report questioned
whether 14-3-3 proteins are recruited to TTP in a phosphory-
lation-dependent manner and whether the activation of the
p38 MAPK pathway has any effect upon TTP function (52). In
our hands, TTP activity was modulated but not ablated
through p38 MAPK-dependent phosphorylation of serines 52
and 178 (T. Santalucia, M. Brook, E. Hitti, et al., unpublished).
In that study we also demonstrated that MK2-mediated phos-
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phorylation at serines 52 and 178 promoted redistribution of
TTP from the nucleus to the cytoplasm of HeLa cells.
The impact of the p38 MAPK pathway on TTP expression
and function remains controversial. Several previous studies
have been performed by means of transient transfection of cell
types that normally express little or no TTP. In HeLa cells, the
effects of the p38 MAPK pathway on subcellular localization of
TTP were obscured when the protein was expressed at high
levels (T. Santalucia, M. Brook, E. Hitti, et al., unpublished),
while in 293 cells overexpression of TTP resulted in a para-
doxical stabilization of an ARE-containing reporter mRNA
(36). In lipopolysaccharide (LPS)-treated RAW 264.7 cells, as
many as 10 distinct, differentially phosphorylated forms of TTP
can be resolved by polyacrylamide gel electrophoresis (PAGE)
and detected by Western blotting, suggesting that its posttrans-
lational modification is highly complex (M. Brook, unpublished
observations) and that additional phosphorylation events re-
main to be identified. Indeed, while the manuscript was in
revision, Cao et al. have described over 30 putative phosphor-
ylation sites in human TTP for which functions remain to be
determined (7). In contrast, the phosphorylation of TTP in
transfected HeLa cells appears much less complex (T. Santa-
lucia, M. Brook, E. Hitti, et al., unpublished). There is clearly
a case for studying the impact of signaling pathways on the
biology of endogenous rather than exogenous TTP. Where this
is not possible, great care should be taken to avoid overexpres-
sion of the protein, which is likely to give rise to artifacts. With
this in mind, we undertook a study of the effects of p38 MAPK
and other signaling pathways on endogenous TTP in RAW
264.7 cells and primary murine or human myeloid cells, all of
which express TTP when stimulated with LPS. We also opti-
mized a transfection procedure to express exogenous TTP in
myeloid cells at levels similar to those of the endogenous
protein. We present evidence for complex posttranslational
regulation of TTP by the extracellular signal-regulated kinase
(ERK) and p38 MAPK pathways.
MATERIALS AND METHODS
Materials. All reagents were purchased from Merck Biosciences, Ltd., unless
stated otherwise. Salmonella enterica serovar Typhimurium LPS was from Sigma-
Aldrich Company, Ltd., and was used at a concentration of 10 ng/ml. The rabbit
polyclonal antiserum against the N terminus of mouse TTP was described previously
(47). Cycloheximide (Cx), wide-range sodium dodecyl sulfate (SDS)-PAGE molec-
ular weight markers and a mouse monoclonal antibody against -tubulin were from
Sigma-Aldrich. SeeBlue prestained SDS-PAGE molecular weight markers were
from Invitrogen. Rabbit anti-phospho-p38 MAPK (Thr180/Tyr182) antibody was
from Cell Signaling Technology, mouse anti-lamin A/C antibody was from Becton
Dickson, and rabbit anti-green fluorescent protein (GFP) antibody was from Abcam.
GFP-TTP expression plasmids were constructed by subcloning the previously de-
scribed wild-type and S52/178A mutated murine TTP cDNAs (60) into peGFPc1
(BD Clontech). Immortalized MK2/ macrophages were provided by Matthias
Gaestel (Medical School, Hannover, Germany) and have been described previously
(26a). MSK-1/ MSK-2/ mice have been described previously (55). CPG57380
was a kind gift of Philip Cohen (MRC Protein Phosphorylation Unit, University of
Dundee, Dundee, United Kingdom).
Cell culture. RAW 264.7 cells (ATCC TIB-71) and immortalized MK2/
macrophages were cultured in Dulbecco’s modified Eagle’s medium (Labtech)
supplemented with 10% (vol/vol) fetal calf serum (PAA) in a humidified atmo-
sphere of 5% CO2 at 37°C.
Primary cell isolation. Elutriation of human monocytes was performed as
described previously (20), and cells were cultured in RPMI 1640 supplemented
with 1% (vol/vol) fetal calf serum (PAA) in a humidified atmosphere of 5% CO2
at 37°C. Mouse bone marrow-derived macrophages were isolated as described
previously (44) and were cultured in Dulbecco’s modified Eagle’s medium
(Labtech) supplemented with 10% (vol/vol) fetal calf serum (PAA) and 10 ng/ml
macrophage-colony stimulating factor (Peprotech) in a humidified atmosphere
of 5% CO2 at 37°C.
Cell transfection. Eighty-five percent confluent T150 flasks of macrophages
were seeded into fresh T150 flasks at a ratio of 1:2 and cultured overnight in
standard conditions. Prior to transfection, the cells were scraped into RPMI 1640
containing 20% (vol/vol) fetal calf serum and then pelleted at 600  g for 5 min.
Cells (2  106) were resuspended in 100 l Nucleofection Solution T (Amaxa)
and mixed with 5 g LPS-free plasmid DNA containing 500 ng peGFPc1 and/or
peGFPc1-TTP or peGFPc1-TTP S52/178A in an electroporation cuvette. The
cells were electroporated using the Nucleofector device (Amaxa) program T-20
and immediately resuspended in RPMI 1640 containing 20% (vol/vol) fetal calf
serum. Identical transfections were pooled to control for differences in transfec-
tion efficiency prior to seeding for culture into 6-well plates. For protein stability
experiments, cells were cultured for 2 h and then either left unstimulated or
treated with LPS for 2 h prior to harvest or treatment with cycloheximide and
dimethyl sulfoxide (DMSO) or kinase inhibitors for a further 2 h. In some
experiments, GFP expression was monitored by fluorescence microscopy or flow
cytometry to quantify transfection efficiencies.
Preparation of cell extracts. All operations were performed at 0 to 4°C. The
cells were rinsed twice with phosphate-buffered saline (PBS) and harvested by
scraping. The cells were then pelleted by centrifugation at 600  g for 10 min.
Whole-cell extracts were generated by lysing the cells in 1 Laemmli sample
buffer for 5 min, after which the genomic DNA was sheared using a Qiashredder
column (QIAGEN) according to the manufacturer’s recommendations. Cyto-
plasmic extracts were prepared by lysing the cells for 5 min in cytoplasmic
extraction buffer (10 mM HEPES, pH 7.6, 3 mM MgCl2, 40 mM KCl, 50 mM
sodium -glycerophosphate, 5% [vol/vol] glycerol, 0.5% [vol/vol] Igepal CA630,
2 mM NaF, 1 mM sodium orthovanadate [all from Sigma-Aldrich]) containing 1
M microcystin-LR (Merck Biosciences-Calbiochem), 2 mM dithiothreitol
(DTT), 1 mM phenylmethylsulfonyl fluoride, 10 M E64, 1 g/ml pepstatin A,
and 10 g/ml aprotinin (all Sigma-Aldrich). Nuclei were pelleted by centrifuging
at 600  g for 5 min, and the supernatant was retained as cytoplasmic extract.
The nuclei were then washed by gentle pipetting in nuclei wash buffer (10 mM
HEPES, pH 7.6, 1.5 mM MgCl2, 10 mM KCl, 50 mM sodium -glycerophos-
phate, 2 mM NaF, 1 mM sodium orthovanadate) containing 1 mM DTT, 1 M
microcystin-LR, 1 mM phenylmethylsulfonyl fluoride, 10 M E64, 1 g/ml pep-
statin A, and 10 g/ml aprotinin and pelleted by centrifuging at 600  g for 5
min. The supernatant was discarded, and the nuclei were resuspended in an
equal volume of nuclei wash buffer to that used for cytoplasmic extraction buffer
and lysed by the addition of 4 Laemmli sample buffer to a final concentration
of 1. The genomic DNA was sheared using a Qiashredder column as per
whole-cell extract production. Protein concentrations were determined by Brad-
ford protein assay.
Western blotting. Cell extracts were prepared as described above, separated by
SDS-PAGE, and electrophoretically transferred to polyvinylidene fluoride mi-
croporous membrane (Perkin Elmer). Immunoblotting was performed using
standard procedures with primary antibody at either a 1:1,000 dilution or the
manufacturer’s recommended dilution. Horseradish peroxidase-coupled second-
ary antibodies (Dako) were then used according to the manufacturer’s instruc-
tions, and the activity was detected using an enhanced chemiluminescence system
(GE Healthcare).
Northern blotting. RNA was purified from RAW 264.7 cells using QIAamp
RNA blood kits (QIAGEN). For each experimental time point, 10 g of total
RNA was subjected to denaturing electrophoresis as described previously (5). A
previously described 1-kb full-length murine TTP cDNA probe (60) was labeled
using ReadyToGo reagents (GE Healthcare) in the presence of 50 Ci of
[-32P]dCTP (3,000 Ci/mmol) (GE Healthcare). Prior to transfer of the gel, 18S
rRNA levels were visualized by staining with Sybr green II (Invitrogen-Molecular
Probes) and quantified using a phosphorimager (FLA2000; Fuji). RNAs were
capillary transferred onto a nylon membrane (Hybond XL; GE Healthcare) prior
to blotting using Ultrahyb blotting solution (Ambion) according to the manu-
facturer’s recommendations.
RNase protection assay. Assays were performed using the DirectProtect
RNase protection assay kit (Ambion) according to the manufacturer’s recom-
mendations. Riboprobes complementary to murine TTP and murine TNF-
were described previously (60), and a riboprobe template (pTriGAPDH) com-
plementary to murine GAPDH was from Ambion.
Quantitative reverse transcription-PCR. PCR was carried out as described
previously (17). Briefly, TTP mRNA levels were quantified in duplicate PCRs on
two independent macrophage preparations per genotype. In addition, we both
confirmed the efficiency of the PCR and cloned and sequenced the PCR product
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to ensure high-fidelity amplification of TTP cDNA. PCR primers were as follows:
5, TCGGACCTACTCAGAAAGC; 3, GGTAGAACTTGTGGCAGAG.
RESULTS
p38 MAPK and ERK signaling pathways regulate TTP ex-
pression, phosphorylation, and subcellular localization. TTP
is rapidly induced in macrophages following LPS stimula-
tion, is highly phosphorylated, and is almost exclusively cy-
toplasmic (9, 47). We previously demonstrated that p38
MAPK controls the expression of TTP via regulation of
mRNA stability (60). In the presence of a p38 MAPK inhibitor,
LPS-induced TTP levels were significantly reduced, but the resid-
ual protein was still highly phosphorylated (Fig. 1A and B), sug-
gesting a role for kinases other than p38 MAPK in both the
phosphorylation and expression of TTP. To identify kinase
pathways involved in regulating TTP expression and phos-
phorylation, RAW 264.7 cells were treated with LPS in
the presence or absence of various kinase inhibitors (Fig. 1A).
SP600125 (a Jun N-terminal protein kinase inhibitor), Rott-
lerin (an inhibitor of several protein kinase C isoforms), or
LY294002 (an inhibitor of phosphatidylinositol 3-kinase) did
not block the induction of TTP protein by LPS. Only the p38
MAPK inhibitor SB202190 modulated TTP expression. As
previously described (60), the MEK1/ERK pathway inhibitor
U0126 did not block TTP expression. However, U0126 repro-
ducibly caused an increase in the electrophoretic mobility of
TTP, suggesting a reduction in phosphorylation (Fig. 1B; see
also Fig. 3 and 4A and B; note that the pattern of migration of
TTP bands varies slightly according to conditions of electro-
phoresis and extract preparation). The inhibition of both the
ERK and p38 MAPK pathways by simultaneous addition of
U0126 and SB202190 resulted in a complete blockade of LPS-
induced TTP expression (Fig. 1B). This synergistic inhibition
of TTP expression by simultaneous SB202190 and U0126 ad-
dition was not observed when steady-state TTP mRNA levels
were examined (Fig. 1C). As previously described, a p38
MAPK inhibitor dose dependently reduced TTP mRNA levels
(60), but U0126 had no additive effect at doses that completely
block the activation of ERK. These results indicate that the
ERK and p38 MAPK pathways synergistically regulate TTP
expression at a translational and/or posttranslational level.
TTP protein stability is regulated by the p38 MAPK path-
way. To examine the possible posttranslational regulation of
TTP levels by p38 MAPK, SB202190 was added to LPS-stim-
ulated RAW 264.7 cells for various times in the presence or
absence of cycloheximide (Cx) (Fig. 2A). Between 2 and 4 h
after the addition of LPS, the expression of TTP protein in-
creased, but its electrophoretic mobility did not change. In the
presence of Cx, the electrophoretic mobility and quantity of
TTP remained relatively constant over the same time course,
consistent with a reported protein half-life of greater than 4 h
(9). In the absence or presence of Cx, addition of SB202190
resulted in a rapid change in electrophoretic mobility of TTP
and a decrease in its quantity, consistent with a decrease of
protein half-life to approximately 30 min.
Similar experiments were performed using primary murine
macrophages (Fig. 2B, left panel) and human monocytes (Fig.
2B, right panel). In each case the addition of SB202190 re-
sulted in complete clearance of TTP protein within two hours
in translationally arrested cells. To investigate the role of MK2
in the regulation of TTP protein stability, we performed similar
experiments in immortalized macrophages derived from
MK2/ or control mice (Fig. 2C). Note that the expression of
TTP was lower in MK2/ macrophages (26a); therefore, three
times as much extract from these cells was loaded for Western
blotting. In immortalized wild-type macrophages, TTP protein
was relatively stable and again was significantly destabilized
following inhibition of the p38 MAPK pathway. TTP was
somewhat less stable in immortalized MK2/ macrophages
(compare lanes 2 and 6 as well as 12 and 16). However, sig-
nificant destabilization was still observed following addition of
SB202190. These observations suggest that, in monocytic cell
types, LPS-induced TTP is posttranslationally stabilized by the
p38 MAPK pathway and that this is mediated, in part, by MK2.
ERK and p38 MAPK pathways synergistically regulate sta-
bility and subcellular localization of TTP. We have found that
the p38 MAPK pathway regulates subcellular localization of
TTP in HeLa cells and primary murine macrophages, promot-
ing its translocation from the nucleus to the cytoplasm (T.
FIG. 1. TTP protein, but not mRNA expression, is synergistically
regulated by the p38 MAPK and ERK pathways. (A and B) RAW
264.7 cells were either left unstimulated or stimulated with LPS for 2 h
in the presence of either 0.1% DMSO, 1 M SB202190, 10 M U0126,
50 M SP600125, 10 M Rottlerin, or 10 M LY294002. Whole-cell
extracts were prepared, and TTP and tubulin were detected by West-
ern blotting. Positions of molecular mass markers (in kilodaltons) are
indicated. (C) RAW 264.7 cells were left unstimulated or stimulated
with LPS for 2 h in the presence of 0.1% DMSO or the indicated
concentrations of SB202190 or U0126. TTP mRNA was detected by
Northern blotting and normalized against 18S rRNA. NT, untreated.
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Santalucia, M. Brook, E. Hitti, et al., unpublished). As de-
scribed above, p38 MAPK also regulates the stability of TTP
protein in myeloid cells and synergizes with the ERK pathway
to regulate expression of TTP at a posttranslational level. We
therefore investigated the effects of an inhibitor of the ERK
pathway on the stability and subcellular localization of TTP in
RAW 264.7 cells.
Following stimulation with LPS for 2 h, vehicle, SB202190,
U0126, or both inhibitors were added to cells in the presence
of Cx (Fig. 3). Inhibition of p38 MAPK caused a rapid dephos-
phorylation and an increase in nuclear levels of TTP protein
within 5 min, with a reduction of steady-state TTP protein
levels at later time points as previously shown. -Tubulin was
blotted as a marker of the cytoplasmic fraction, and lamin A/C
was blotted as a marker of the nuclear fraction. Even in very
long exposures of Western blots (data not shown), we were
unable to detect -tubulin in the nuclear fraction or lamin A/C
in the cytoplasmic fraction, confirming the integrity of the
subcellular fractions. Therefore, the p38 MAPK pathway reg-
ulates subcellular localization of TTP in RAW 264.7 cells as it
does in HeLa cells and primary murine macrophages (T. Santa-
lucia, M. Brook, E. Hitti, et al., unpublished). Inhibition of
the ERK pathway resulted in a more subtle change in TTP
phosphorylation status and no change in its subcellular distri-
bution or stability. Simultaneous inhibition of both the p38
MAPK and ERK pathways resulted in enhanced nuclear ac-
cumulation of TTP relative to that caused by a p38 MAPK
inhibitor alone (Fig. 3, compare lanes 7 to 9 with lanes 15 to
17). The electrophoretic mobility of TTP was also increased,
suggesting a greater degree of dephosphorylation. Further-
more, the combination of inhibitors caused a synergistic desta-
bilization of TTP protein. In separate experiments employing
whole-cell extracts rather than nuclear and cytoplasmic ex-
tracts, we estimated that TTP protein was degraded with a
half-life between 5 and 10 min in the presence of both
FIG. 2. TTP protein stability is regulated by the p38 MAPK pathway.
(A) RAW 264.7 cells were either left unstimulated, stimulated with LPS
for 2 h, or stimulated with LPS for 2 h and then treated with 0.1% DMSO
or 1 M SB202190 for the times indicated (upper panel) or stimulated
with LPS for 1.75 h and then treated with Cx (5 g/ml) for 15 min prior
to the addition of 0.1% DMSO or 1 M SB202190 (lower panel) for the
times indicated. (B) Primary mouse bone marrow-derived macrophages
(BMDM) (left panel) or primary human monocytes (right panel) were
either left unstimulated, stimulated with LPS for 2 h in the presence or
absence of 1 M SB202190, or stimulated with LPS for 1.75 h and then
treated with Cx (5 g/ml) for 15 min prior to the addition of 0.1% DMSO
or 1 M SB202190 for a further 2 h. (C) Immortalized wild-type or
MK2/ macrophages were either left unstimulated or stimulated with
LPS for 1.75 h and then treated with Cx (5 g/ml) for 15 min prior to the
addition of 0.1% DMSO or 1 M SB202190 for the times indicated; 100
g wild type and 300 g MK2/ extract were loaded for blotting. In each
case (A to C), whole-cell extracts were prepared and TTP and tubulin
were detected by Western blotting. Positions of molecular mass markers
(in kilodaltons) are indicated. NT, untreated.
FIG. 3. TTP protein stability and subcellular localization are syn-
ergistically regulated by the p38 MAPK and ERK pathways. RAW
264.7 cells were either left unstimulated, stimulated with LPS for 2 h,
or stimulated with LPS for 1.75 h and then treated with Cx (5 g/ml)
for 15 min prior to the addition of 0.1% DMSO, 1 M SB202190,
and/or 10 M U0126 for the times indicated. Cytoplasmic (cyto.) and
nuclear (nuc.) extracts were prepared, and TTP, tubulin, and lamin
A/C were detected by Western blotting (tubulin was not detected in
the nuclear fraction, and lamin A/C was not detected in the cytoplas-
mic fraction). Positions of molecular mass markers (in kilodaltons) are
indicated. Equivalent exposures (expos.) (30 s) of the cytoplasmic and
nuclear TTP signals and an extended exposure (3 min) of the nuclear
TTP signal are shown. NT, untreated.
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SB202190 and U0126 (data not shown). Thus, the p38 MAPK
and ERK pathways synergistically regulate both the subcellular
distribution and the stability of TTP protein. Inhibition of
these signaling pathways results in rapid dephosphorylation of
TTP by an unknown phosphatase or phosphatases, nuclear
accumulation, and protein destabilization.
It is known that ERK and p38 MAPK can synergistically
activate several downstream kinases, such as MSK-1 and
MSK-2 (19, 48) as well as MNK-1 and MNK-2 (30, 63, 64).
Therefore, we used inhibitors to investigate the roles of these
kinases in the regulation of TTP. CPG57380 inhibits MNK-1
and -2 with a 50% inhibitory concentration of 2.2 M (30);
however, 10 M CPG57380 did not alter the expression, sub-
cellular localization, or stability of TTP (Fig. 4A), whereas the
combination of SB202190 and U0126 caused destabilization
and relocalization of TTP protein as before. H89 and Ro
31-8220 inhibit MSK-1 and -2 but do not significantly affect
ERK, p38 MAPK, or MK2 (18). Neither of these inhibitors
FIG. 4. MSK-1 and -2 but not MNK-1 and -2 regulate TTP protein induction but not its stability or subcellular localization. (A) RAW 264.7
cells were either left unstimulated, stimulated with LPS for 2 h in the presence or absence of the indicated doses of CPG57380 (CPG), 1 M
SB202190 (SB), and/or 10 M U0126 (U), or stimulated with LPS for 1.75 h and then treated with Cx (5 g/ml) for 15 min prior to the addition
of 0.1% DMSO, the indicated doses of CPG57380, 1 M SB202190, and/or 10 M U0126 for the times indicated. An extended exposure (expos.)
(5 min) of the nuclear TTP signal is shown. (B) As for panel A, except that the inhibitors used were as follows: 25 M H89, 5 M Ro 31-8220,
1 M SB202190, and/or 10 M U0126. An extended exposure (5 min) of the nuclear TTP signal is shown. In each case (A and B), cytoplasmic
(cyto.) and nuclear (nuc.) extracts were prepared, and TTP, tubulin, and lamin A/C were detected by Western blotting (tubulin was not detected
in the nuclear fractions, and lamin A/C was not detected in the cytoplasmic fraction). (C) RAW 264.7 cells were either left unstimulated or treated
with 0.1% DMSO, 10 M MG132 (MG), 25 M H89, or 5 M Ro 31-8220 (Ro) for 30 min prior to being treated with LPS for 2 h. Total RNA
was prepared, and 4 g RNA/point was analyzed by RNase protection assay for the expression of TTP mRNA (black bars) and TNF- mRNA
(gray bars). (D) Wild-type (open bars) and MSK-1/ MSK-2/ macrophages (black bars) were either left unstimulated or treated with LPS for
the times indicated. Total RNA was prepared, and TTP mRNA levels were measured using quantitative reverse transcription-PCR. Means 
standard deviations are shown for duplicate PCRs on two independent macrophage preparations per genotype. (E) Wild-type and MSK-1/
MSK-2/ macrophages were either left unstimulated or were treated with 0.1% DMSO, 25 M H89, or 1 M SB202190 for 30 min prior to being
treated with LPS for 2 h. Whole-cell extracts were prepared for Western blotting. Positions of molecular mass markers (in kilodaltons) are
indicated in each case. An asterisk indicates a nonspecific band.
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altered the subcellular localization or stability of TTP (Fig.
4B), suggesting that the synergistic posttranslational regulation
of TTP by ERK and p38 MAPK pathways is not mediated by
MSK-1 or -2. On the other hand, the induction of TTP protein
by LPS was inhibited by either H89 or Ro 31-8220 (Fig. 4B).
The induction of TTP mRNA by LPS was also significantly
inhibited by either H89 or Ro 31-8220, whereas the induction
of TNF- mRNA was not significantly altered (Fig. 4C). In
LPS-stimulated RAW 264.7 cells, the activation of MSK-1 and
-2 is principally mediated by p38 MAPK (6). The small input
from ERK in this context may account for the lack of inhibition
of TTP expression by U0126 alone. MG132, an inhibitor of the
proteasome, inhibited the induction of both TNF- and TTP
mRNAs.
H89 and Ro 31-8220 are not highly specific inhibitors of
MSK-1 and -2, but they block a number of other signaling
pathways (18). More selective inhibitors of other potential H89
and Ro 31-8220 targets did not prevent the induction of TTP
mRNA by LPS (data not shown). To provide more conclusive
evidence of a role for MSK-1 and -2 in the expression of TTP,
we studied LPS-treated bone marrow macrophages derived
from an MSK-1/ MSK-2/ mouse strain. At both mRNA
and protein levels, the expression of TTP was lower in MSK-1/
MSK-2/ than in wild-type murine macrophages (Fig. 4D and
E). Because of exceptionally weak expression of TTP protein,
we were unable to assess the role of MSK-1 and -2 in its
posttranslational regulation. Taken together with the inhibitor
studies, these data indicate that MSK-1 and/or MSK-2 are
required for efficient induction of TTP mRNA but that MSK-1
and -2 or MNK-1 and -2 do not contribute to the synergistic
posttranslational regulation of TTP by ERK and p38 MAPK
pathways.
TTP protein stability and subcellular localization are regu-
lated by phosphorylation of serines 52 and 178. In vitro, MK2
phosphorylates TTP at serines 52 and 178 (15, 47) (T. Santa-
lucia, M. Brook, E. Hitti, et al., unpublished). Mass spectro-
metric studies provide evidence for phosphorylation of these
sites in vivo (7, 15). This is also supported by differences in
electrophoretic mobility between endogenous TTP expressed
in wild-type and MK2/ macrophages (Fig. 2C), GFP-TTP
and GFP-TTP-S52A/S178A (Fig. 5B), or Flag-TTP and Flag-
TTP-S52A/S178A (T. Santalucia, M. Brook, E. Hitti, et al.,
unpublished). We have previously described a role for these
phosphorylation sites in the regulation of nucleocytoplasmic
localization of exogenous TTP in HeLa cells (T. Santalucia, M.
Brook, E. Hitti, et al., unpublished). In order to assess the role
of these phosphorylations in macrophages, we optimized a
protocol for transfection of RAW 264.7 cells. Transfection
efficiencies of 	60 to 70% were routinely achieved (as ascer-
tained by flow cytometry and microscopic analysis; data not
shown), and as little as 500 ng of plasmid was sufficient to
express GFP-tagged TTP at levels similar to those observed for
endogenous TTP (data not shown). Unsurprisingly, the elec-
troporation procedure caused transient activation of the p38
MAPK pathway (Fig. 5A), and this was reflected by a weak
induction of endogenous TTP expression (Fig. 5B). When
RAW 264.7 cells were transfected with a GFP expression vec-
tor, fluorescent cells were readily detected after 24 or 48 h. In
contrast, when a GFP-TTP expression vector was used, we
could scarcely detect fluorescent cells after 16 h (data not
shown). To investigate this phenomenon further, we cotrans-
fected RAW 264.7 cells with equal amounts of GFP and GFP-
TTP expression vectors and assessed the expression of both
proteins over 24 h. When detected using an anti-GFP antibody,
GFP and GFP-TTP both comigrated with nonspecific bands
(Fig. 5A, upper panel, indicated by an asterisk). However, GFP
FIG. 5. TTP stability and subcellular localization are regulated by
MK2-mediated phosphorylation of serines 52 and 178. (A) RAW 264.7
cells were either left untreated or transfected with peGFPc1-TTP and
cultured for the times indicated following transfection. Whole-cell
extracts were prepared, and GFP-TTP, GFP, phospho-p38 (P-p38)
MAPK, and tubulin were detected by Western blotting (W blot).
Asterisks indicate nonspecific bands detected by the anti-GFP anti-
body. (B) RAW 264.7 cells were transfected with either peGFPc1-TTP
or peGFPc1-TTP-S52/178A and then cultured for 2 h. Cells were then
either harvested, treated with LPS for 2 h, or treated with LPS for
1.75 h and then treated with 5 g/ml Cx for 15 min prior to the addition
of 0.1% DMSO or 1 M SB202190 for a further 2 h. Cytoplasmic
(cyto.) and nuclear (nuc.) extracts were prepared, and TTP, tubulin,
and lamin A/C were detected by Western blotting (tubulin was not
detected in the nuclear fractions, and lamin A/C was not detected in
the cytoplasmic fraction). Positions of molecular mass markers (in
kilodaltons) are indicated.
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was detectable from 2 h posttransfection and was sustained for
at least 24 h, whereas expression of GFP-TTP was weak and
declined after 8 h. The expression pattern of GFP-TTP was
confirmed using an anti-TTP antibody (Fig. 5A). This obser-
vation suggests that the decline in expression of GFP-TTP is
not caused by apoptosis of transfected cells but may be related
to the stability of the GFP-TTP fusion protein.
GFP-TTP was expressed at low levels in unstimulated RAW
264.7 cells (Fig. 5B) and was significantly upregulated and
phosphorylated following treatment with LPS for 2 h. GFP-
tagged TTP in which serines 52 and 178 were mutated to
alanine (GFP-TTP-S52/178A) was consistently expressed at
lower levels than GFP-TTP and was only weakly upregulated
and phosphorylated upon LPS stimulation (Fig. 5B). The se-
lective upregulation of GFP-TTP but not GFP-TTP-S52A/
S178A rules out a transcription-mediated response and sug-
gests different posttranslational processing of the two proteins.
Like endogenous TTP protein, GFP-TTP remained relatively
stable for 2 h following the addition of Cx, but it was rapidly
degraded if the p38 MAPK pathway was simultaneously inhib-
ited. In contrast, GFP-TTP-S52A/S178A was degraded rapidly
whether the p38 MAPK pathway was inhibited or not. The two
proteins also behaved differently in terms of their subcellular
localization: GFP-TTP was almost undetectable in the nucleus,
whereas GFP-TTP-S52A/S178A was readily detected in the
nuclear fraction. Hence, the posttranslational regulation of
TTP protein stability and subcellular localization is, at least
partly, dependent on the integrity of serine 52 and/or 178.
TTP degradation requires phosphatase activity and proceeds
via the proteasome. LPS-induced TTP protein is rapidly de-
phosphorylated following p38 MAPK inhibition, suggesting
that TTP is subject to dynamic regulation by kinase and phos-
phatase activities. The dephosphorylated TTP is rapidly de-
graded, leading us to hypothesize that the protein may be
targeted for destruction by the 20S/26S proteasomes. The
mechanism of TTP turnover was investigated further using
inhibitors specific for serine/threonine (ser/thr) phosphatases
(calyculin A) or the 20S/26S proteasomes (MG132). RAW
264.7 cells were either left unstimulated, stimulated with LPS
for 2 h in the presence or absence of inhibitors, or stimulated
with LPS for 2 h prior to addition of vehicle or inhibitor in the
presence of Cx (Fig. 6A). The LPS-induced expression of TTP
protein was enhanced by calyculin A (Fig. 6A, lanes 1, 4, and
6), possibly due to increased activation of the p38 MAPK
signaling pathway (data not shown). In contrast, TTP induction
was blocked by Cx, SB202190, or MG132 (Fig. 6A, lanes 2, 3,
and 5). TTP protein was relatively stable for the duration of the
2-h translational arrest but was destabilized by addition of
SB202190 (Fig. 6A, compare lanes 6, 7, and 10). This destabi-
lization was significantly reduced in the presence of either
phosphatase or proteasome inhibitor (Fig. 6A, compare lane
10 to lane 12). Thus, we conclude that the p38 MAPK pathway
phosphorylates and stabilizes TTP and that acute inhibition of
p38 MAPK causes rapid TTP dephosphorylation by an un-
FIG. 6. TTP turnover proceeds via the proteasome and is nega-
tively regulated by p38 MAPK-mediated phosphorylation. (A) RAW
264.7 cells were either left unstimulated, treated with LPS for 2 h in the
presence or absence of the indicated inhibitors, or treated with LPS for
1.75 h and then treated with 5 g/ml Cx and/or 10 M MG132 or 100
nM calyculin A for 15 min prior to the addition of 0.1% DMSO or 1
M SB202190 for a further 2 h. Whole-cell extracts were prepared and
TTP and tubulin were detected by Western blotting. Positions of mo-
lecular mass markers (in kilodaltons) are indicated. (B) RAW 264.7
cells were either left unstimulated, treated with LPS for 2 h in the
presence or absence of 5 g/ml Cx, 1 M SB202190, or 10 M MG132,
or treated with LPS for 1.75 h and then treated with 5 g/ml Cx and
increasing concentrations of MG132 for 15 min prior to the addition of
1 M SB202190 for a further 2 h. Cytoplasmic (Cyto.) and nuclear
(Nuc.) extracts were prepared, and TTP, tubulin, and lamin A/C were
detected by Western blotting (tubulin was not detected in the nuclear
fraction, and lamin A/C was not detected in the cytoplasmic fraction).
(C) RAW 264.7 cells were either LPS stimulated for 4 h or treated with
LPS for 2 h and then treated with 10 nM calyculin A for a further 2 h.
Complete cell extracts were prepared and either left untreated or
incubated with 50 U shrimp alkaline phosphatase for 2 h at 37°C prior
to Western blotting. Positions of molecular mass markers (in kilo-
daltons) are indicated. An asterisk indicates a novel 	63-kDa form
of TTP.
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known ser/thr phosphatase. Once dephosphorylated, the TTP
is targeted to the proteasome by an unknown mechanism and
rapidly degraded.
Interestingly, in the presence of both SB202190 and MG132,
the majority of TTP protein exhibited increased electro-
phoretic mobility (Fig. 6A, compare lane 7 to lane 12), sug-
gesting that the proteasome inhibitor may protect a dephos-
phorylated form of TTP from degradation. We hypothesized
that the dephosphorylated TTP would have an altered subcel-
lular distribution. To test this hypothesis, we prepared nuclear
and cytoplasmic extracts from RAW 264.7 cells that were ei-
ther untreated, stimulated with LPS for 2 h in the presence or
absence of inhibitors, or stimulated with LPS for 2 h before
addition of vehicle or inhibitors in the presence of Cx for a
further 2 h. After 2 h of LPS treatment, TTP was largely
cytoplasmic and phosphorylated (Fig. 6B, lanes 1 and 5). After
a further 2 h of translational arrest, TTP levels were unchanged
and the protein was highly phosphorylated and predominantly
cytoplasmic (Fig. 6B, lanes 5 and 6). The combination of Cx
and SB202190 resulted in dephosphorylation and degradation
of TTP (Fig. 6B, lanes 6 and 7). The addition of MG132 to
these cells caused a dose-dependent reversal of the TTP-de-
stabilizing effects of SB202190, with 10 M MG132 blocking
the effects of p38 MAPK inhibition. However, this protected
TTP was dephosphorylated and predominately nuclear (Fig.
6B, compare lanes 6 and 12).
In extracts of calyculin A-treated cells, and more weakly in
MG132-treated cells, we detected a low-mobility TTP form of
an apparent molecular mass of 	63 kDa (identified by an
asterisk in Fig. 6A). Phosphatase treatment of cell extracts
caused collapse of all TTP bands, including the 63-kDa band,
to faster migrating positions, suggesting that the 63-kDa form
of TTP is hyperphosphorylated. However, the TTP bands did
not collapse to a single position. We conclude that either some
phosphorylations are resistant to dephosphorylation in vitro or
additional posttranslational modifications of TTP remain to be
identified.
DISCUSSION
The p38 MAPK signaling pathway regulates expression of
many inflammatory mediators at a posttranscriptional level via
MK2-mediated stabilization of otherwise highly labile mRNAs
(16, 22). At least some of these inflammatory mediators are
also known to be posttranscriptionally controlled by TTP, a
well-characterized mRNA destabilizing factor. The reasons for
studying functional links between p38 MAPK and TTP are
therefore clear, yet there remains controversy over whether
TTP is a substrate of p38 MAPK itself, MK2, or both (8, 10, 15,
47, 67); whether or not such phosphorylation alters TTP func-
tion (52, 56) (T. Santalucia, M. Brook, E. Hitti, et al., unpub-
lished); and whether or not it results in recruitment of 14-3-3
proteins (15, 52, 56). Several previous studies have been per-
formed using cell types that express little or no endogenous
TTP and in which overexpression of the protein may subvert
the normal regulation of stability, localization, or function.
With this in mind, here we performed experiments using RAW
264.7 cells, primary monocytes, or macrophages that all express
TTP in response to LPS. We also optimized a transfection
protocol that allowed expression of exogenous TTP at levels
similar to those of endogenous protein.
We describe evidence that the p38 MAPK signaling pathway
regulates the stability of TTP protein in myeloid cells via MK2-
mediated phosphorylation of serines 52 and 178. (i) In cyclo-
heximide chase experiments performed in RAW 264.7 cells, a
p38 MAPK inhibitor destabilized endogenous TTP protein,
reducing its half-life from
4 h to approximately 30 min. (ii) In
primary human monocytes or murine macrophages, endoge-
nous TTP protein was even more strikingly destabilized fol-
lowing inhibition of p38 MAPK. (iii) LPS-induced TTP protein
displayed weaker expression and lower stability in immortal-
ized MK2/ macrophages than in wild-type control cells. (iv)
In transfected RAW 264.7 cells, a GFP-TTP fusion protein was
expressed only transiently. This was correlated with a transient
activation of the p38 MAPK pathway caused by the transfec-
tion procedure. (v) Expression of GFP-TTP was further en-
hanced by stimulation of RAW 264.7 cells with LPS. This
upregulation was not observed with a GFP-TTP fusion protein
lacking the major MK2 phosphorylation sites, and it was in-
hibited by SB202190 (data not shown). We observed little or
no LPS-induced increase in expression of GFP-TTP in trans-
fected MK2/ macrophages, but unfortunately we could not
transfect the paired wild-type macrophages to provide an ap-
propriate control for this experiment (data not shown). (vi) In
transfected RAW 264.7 cells, GFP-TTP protein was strongly
destabilized by SB202190, whereas the mutant protein lacking
the MK2 phosphorylation sites was inherently unstable in the
absence or presence of SB202190.
There is also evidence that TTP stability may be regulated
by p38 MAPK in an MK2-independent manner, since
SB202190 still destabilizes TTP protein in MK2/ cells.
Furthermore, we have shown that TTP stability is synergis-
tically regulated by ERK and p38 MAPK pathways. This
posttranscriptional synergy was not mediated by down-
stream kinases MSK-1 or -2 as well as MNK-1 or -2, which
are known to be activated by both ERK and p38 MAPK. A
recent publication describes the identification of several
sites of phosphorylation of TTP in vivo, many of which are
potential targets for members of the MAPK pathway (7).
Our future experiments will determine whether the stability
of TTP is modulated via direct phosphorylation by ERK or
p38 MAPK. Serine 220 was previously identified as a puta-
tive site of direct phosphorylation of TTP by ERK, but no
function has yet been ascribed to this phosphorylation (36,
58, 59).
In RAW 264.7 cells that had been treated with LPS for 2 h,
the addition of SB202190 caused a rapid change in the elec-
trophoretic mobility of endogenous TTP that was indicative of
dephosphorylation and preceded TTP degradation. Calyculin
A, an inhibitor of serine/threonine phosphatases, protected
TTP from SB202190-induced degradation and caused accumu-
lation of a low-mobility, apparently hyperphosphorylated form
of the protein. Hence, the phosphorylation status of TTP de-
pends on a dynamic equilibrium of kinase and phosphatase
activities, dephosphorylation is a prerequisite for protein deg-
radation, and the behavior of TTP is exquisitely sensitive to the
status of the p38 MAPK pathway in myeloid cells that have
been exposed to LPS. We are attempting to identify the puta-
tive TTP phosphatase, which presumably plays an important
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role in determining the course of the inflammatory response.
Importantly, in vitro phosphatase treatment of cell extracts did
not resolve TTP to a single, discrete band, therefore additional
posttranslational modifications of TTP may also remain to be
identified.
MG132 prevented the degradation but not the dephosphor-
ylation of TTP following inhibition of the p38 MAPK pathway;
therefore, a hypophosphorylated form of TTP is targeted for
degradation by the 20S/26S proteasome. This contrasts with
other examples such as IB, in which phosphorylation pre-
cedes polyubiquitination and degradation, leading to activation
of the transcription factor NF-B. Rigby et al. (52) recently
described the existence of putative protein stability-regulating
PEST domains in human TTP. While point mutation of these
domains did not affect the steady-state expression levels of
TTP in HEK 293 cells, the phosphorylation profile of the
proteins was altered. It will be of interest to examine the role
of the PEST domains and their phosphorylation in the p38
MAPK-mediated regulation of TTP stability in monocytic cell
types. MG132 was previously shown to inhibit the decay of
ARE-containing mRNAs, suggesting some form of coupling
between turnover of proteins and mRNAs (42, 43). We were
struck by the similarity in rates of clearance of TTP protein and
TNF- mRNA in SB202190-treated RAW 264.7 cells and by
the observation that ERK and p38 MAPK pathways synergis-
tically regulate the stability of both TTP protein (this work)
and TNF- mRNA (53). However, our preliminary experi-
ments revealed that MG132 decreased rather than increased
the stability of TNF-mRNA (data not shown). Therefore, the
turnover of TTP protein and TNF- mRNA does not appear
to be directly coupled in myeloid cells. The mechanisms de-
scribed here are more likely to play a role in the tight regula-
tion of cellular TTP levels.
In a parallel study (T. Santalucia, M. Brook, E. Hitti et al.,
unpublished), we showed that p38 MAPK-dependent phos-
phorylation of serines 52 and 178 regulated the relocalization
of TTP from the nucleus to the cytoplasm in transfected HeLa
cells. It proved difficult to study this phenomenon in myeloid
cells because of the SB202190-induced destabilization of TTP
protein. However, our results are consistent with a similar
regulation of subcellular localization in these cells. (i) In LPS-
treated RAW 264.7 cells, the addition of SB202190 (alone or in
combination with U0126) caused a rapid increase in nuclear
TTP, accompanied by a change in electrophoretic mobility that
indicated dephosphorylation. (ii) In transfected RAW 264.7
cells, GFP-TTP was almost exclusively cytoplasmic, but a mu-
tant form of this protein lacking the MK2 phosphorylation sites
was detected in both cytoplasmic and nuclear compartments.
In transfected immortalized MK2/ macrophages, GFP-TTP
and the S52/178A mutant were expressed equally strongly in
the nucleus, suggesting that MK2 activity is required for dif-
ferential localization (data not shown). (iii) Most compellingly,
the dephosphorylation of TTP could be uncoupled from its
degradation using a proteasome inhibitor. Under these condi-
tions, TTP was hypophosphorylated and almost exclusively nu-
clear. Although the regulation of TTP subcellular localization
by ERK and p38 MAPK is clear, the function and mechanism
of this regulation are uncertain. It is possible that TTP desta-
bilizes many unidentified mRNAs containing the consensus
binding site UUAUUUAUU (38, 65), several of which encode
regulators of growth and apoptosis (1). We speculate that the
cytoplasmic localization of TTP is tightly regulated in order to
protect cells from the well-characterized proapoptotic conse-
quences of prolonged expression (27, 28). The cytoplasmic
localization of S52/178-phosphorylated TTP may be mediated
by the binding of 14-3-3 proteins (15, 56). Since 14-3-3 proteins
are known to regulate both the localization and stability of
interacting proteins (4, 61, 66), it will be of interest to examine
the role of this interaction in the regulation of TTP turnover.
In the course of these studies, we made some observations
pertaining to the transcriptional control of TTP expression.
First, efficient expression of TTP mRNA was dependent on
MSK-1 and/or MSK-2 being blocked by inhibitors of these
kinases and impaired in murine MSK-1/ MSK-2/ bone
marrow macrophages. TTP may be added to a list of immedi-
ate-early genes, including c-fos, junB, and the nuclear orphan
receptor Nur77, whose expression requires the MSKs (17).
Second, a proteasome inhibitor prevented the induction of
TTP protein and impaired the induction of TTP mRNA in
response to LPS. A possible interpretation is that TTP tran-
scription is regulated by NF-B, since the TTP intron is re-
quired for correct regulation of gene expression and contains a
conserved NF-B consensus sequence (41).
Paradoxically, the p38 MAPK pathway stabilizes proinflam-
matory mRNAs but also stabilizes TTP protein, which has the
opposite effect. In Fig. 7, we present a model for the regulation
of TTP biology by the p38 MAPK pathway during the distinct
phases of an inflammatory response. In unstimulated cells,
containing little or no p38 MAPK activity, TTP is expressed at
low (undetectable) levels and is likely to be hypophosphory-
lated, unstable, and principally nuclear in localization. Upon
stimulation with an inflammatory agonist, p38 MAPK is acti-
vated and expression of both TNF- and TTP is upregulated.
Expression of TTP is tightly coupled to activation of the p38
MAPK pathway via the regulation of mRNA stability and
protein stability, so that the protein accumulates under condi-
tions that favor its phosphorylation. However, TTP phosphor-
ylation impairs its destabilizing function, thereby ensuring that
TNF- mRNA can be expressed and translated. While the p38
MAPK pathway remains active, TTP remains stable, cytoplas-
mic, and inactive. During the resolution of inflammation, p38
MAPK activity declines and TTP is dephosphorylated and
FIG. 7. Model for the regulation of inflammation by p38 MAPK
and TTP. NUC, nuclear; CYTO, cytoplasmic; V, very.
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activated, causing the destabilization of TNF- mRNA. At the
same time, TTP protein begins to relocalize to the nucleus
and/or be degraded by the 20S/26S proteasome. This may
protect the cell from proapoptotic (27) or other undesired
effects of prolonged TTP expression and/or reestablish condi-
tions in which a response to a second proinflammatory stimu-
lus can be mounted. In this model, the p38 MAPK pathway
contributes to both on and off phases of the inflammatory
response. Such a fail-safe mechanism would help to ensure that
disregulation of the p38 MAPK pathway alone is not sufficient
for inappropriate proinflammatory gene expression.
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